AZTR — Azitra, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1701478 ·
Last close
$0.21
Market Cap
$3.40M
52W High
$0.38
52W Low
$0.10
ADV30
563,867
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,933,924 | -3,927,240 | 12,126,804 | 10,051,003 | 1,646,521 |
| Dec 2025 | 0 | — | -2,226,591 | -2,233,504 | 5,025,386 | 2,068,083 | 1,224,156 |
| Sep 2025 | 0 | — | -2,768,484 | -2,764,528 | 4,300,279 | 1,401,878 | 2,021,103 |
| Jun 2025 | 0 | — | -2,871,352 | -2,888,993 | 3,956,022 | 1,045,730 | 1,727,051 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,224,125
Investing CF
$-182,909
Financing CF
$8,920,398
CapEx
$-186,062
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.54
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-68,521,196
Inventory
—
Receivables
$141,295
ST Investments
—
EBIT TTM
$-10,939,464
Pretax Income TTM
$-10,947,051
Interest Exp TTM
$7,587
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -10,966,665 | -10,955,370 | 5,025,386 | 1,224,156 | — | -11,224,125 |
| Dec 2024 | 7,500 | -10,985,140 | -8,967,492 | 7,358,802 | 1,660,504 | — | -10,183,740 |
| Dec 2023 | 686,000 | -7,450,546 | -11,283,781 | 5,115,486 | 2,202,340 | — | -7,362,375 |
| Dec 2022 | 284,000 | -9,453,604 | -10,680,366 | 7,167,443 | 43,427,753 | — | -8,349,469 |
TTM Snapshot
Revenues TTM
$310,700
NetIncome TTM
$-2,952,780
OpCashFlow TTM
$0
Assets (Latest)
$7,358,802
Forward EPS
$-0.52
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. | $3.43M | $0.59 | — |
| BIXT | BIOXYTRAN, INC | $3.47M | $0.03 | — |
| AVCRF | Avricore Health Inc. | $3.29M | $0.03 | — |
| GRI | GRI Bio, Inc. | $3.61M | $2.04 | — |
| CASIF | CASI Pharmaceuticals, Inc. | $3.08M | $0.15 | — |
News headlines (Yahoo Finance, 1h cache)
AZTR: More Background on Cosmetic Opportunity
2026-05-22 11:15 · Yahoo
Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
2026-05-13 12:30 · Yahoo
Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
2026-05-06 12:00 · Yahoo
Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris
2026-04-28 12:02 · Yahoo
Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million
2026-03-19 17:13 · Yahoo
Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement
2026-03-13 21:15 · Yahoo
Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders
2026-03-05 21:30 · Yahoo
AZTR: New Site for ATR-04 Trial
2026-03-04 08:00 · Yahoo
Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates
2026-02-27 22:30 · Yahoo
Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash
2026-02-24 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.